Figure 4
Summary of alterations in CSF ctDNA and metabolites identified in our study. Evaluation of ctDNA and metabolites in CSF has the potential to differentiate patients with GCTs from patients with non-neoplastic diseases and to discriminate patients with NGGCT from patients with germinomas.
